贝伐珠单抗联合化疗方案用于晚期胃癌的临床观察OA北大核心CSTPCD
Clinical Observation of Bevacizumab Combined with Chemotherapy in the Treatment of Advanced Gastric Cancer
目的:探讨贝伐珠单抗联合化疗方案用于晚期胃癌的临床疗效及毒副反应。方法:84例晚期胃癌患者根据随机数字表法分为联合组与化疗组,各42例。化疗组患者采用FOLFOX 4(奥沙利铂+亚叶酸钙+氟尿嘧啶)化疗方案;联合组患者在化疗基础上加用贝伐珠单抗7.5 mg/kg静脉滴注,d1。两组均以21 d为1个周期,连续观察3个周期。比较两组患者的近期疗效、生存质量改善情况、化疗前后血清肿瘤标志物水平及药物毒副反应发生情况。结果:联合组患者的有效率(57.1…查看全部>>
OBJECTIVE:To investigate clinical efficacy and toxic and side effects of bevacizumab combined with chemothera-py in the treatment of advanced gastric cancer. METHODS:84 patients with advanced gastric cancer were randomly divided into combination group and chemotherapy group,with 42 cases in each group. Chemotherapy group received FOLFOX4 chemotherapy regimen(oxaliplatin+calcium folinate+fluorouracil);combination group was additionally given bevacizumab 7.5 m…查看全部>>
王丽红;刘迎;杜晓林
郑州大学附属郑州中心医院消化科,郑州 450000郑州大学附属郑州中心医院消化科,郑州 450000郑州大学附属郑州中心医院消化科,郑州 450000
医药卫生
贝伐珠单抗化疗晚期胃癌疗效毒副反应
BevacizumabChemotherapyAdvanced gastric cancerTherapeutic efficacyToxic and side effects
《中国药房》 2016 (23)
3246-3248,3
评论